Drug resistance in HIV infection;Medikamentell resistens vid HIV-infektion

Tidsskrift for den Norske Laegeforening

Volumn 128, Issue 22, 2008, Pages 2593-2596

  Åsjö, Birgitta ^a,b   Langeland, Nina ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ANTIVIRAL RESISTANCE; ARTICLE; DRUG EFFECT; FOLLOW UP; GENETICS; GENOTYPE; HEALTH; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; INTERNATIONAL COOPERATION; PHENOTYPE; PUBLIC HEALTH; RISK FACTOR; VIRUS REPLICATION;

ANTI-HIV AGENTS; COMMUNICABLE DISEASE CONTROL; DRUG RESISTANCE, VIRAL; FOLLOW-UP STUDIES; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; INTERNATIONAL COOPERATION; PHENOTYPE; PUBLIC HEALTH; RISK FACTORS; VIRUS REPLICATION; WORLD HEALTH;

EID: 56749102601     PISSN: 00292001     EISSN: 08077096     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Barré-Sinoussi F, Chermann JC, Rey F et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983; 220: 868-71.
2. Fischl MA, Richman DD, Grieco MH et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med 1987; 317: 185-91.
3. Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989; 243: 1731-4.
4. Larder BA, Kemp SD. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 1989; 246: 1155-8.
5. Ormaasen V, Sandvik L, Rudberg N et al. Serum concentrations of protease inhibitors as predictors of HIV-related clinical events in patients on antiretroviral therapy. Scand J Infect Dis 2006; 38: 650-3.
6. Hirsch MS, Günthard HF, Schapiro JM et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis 2008; 47: 266-85.
7. Vercauteren J, Vandamme AM. Algorithms for the interpretation of HIV-1 genotypic drug resistance information. Antiviral Res 2006; 71: 335-42.
8. Ormaasen V, Sandvik L, Åsjö B et al. An algorithm-based genotypic resistance score is associated with clinical outcome in HIV-1-infected adults on antiretroviral therapy. HIV Med 2004; 5: 400-6.
9. Weinstein MC, Goldie SJ, Losina E et al. Use of genotypic resistance testing to guide hiv therapy: clinical impact and cost-effectiveness. Ann Intern Med 2001; 134: 440-50.
10. Cohen CJ, Hunt S, Sension M et al. VIRA3001 Study. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS 2002; 16: 579-88.
11. Perez-Elias MJ, Garcia-Arota I, Muñoz V et al. Realvirfen study group. Phenotype or virtual phenotype for choosing antiretroviral therapy after failure: a prospective, randomized study. Antivir Ther 2003; 8: 577-84.
12. Holkmann Olsen C, Mocroft A, Kirk O et al. Euro-SIDA study group. Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death. HIV Med 2007; 8: 96-104.
13. Little SJ, Frost SD, Wong JK et al. Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection. J Virol 2008 ; 82: 5510-8.
14. Delaugerre C, Morand-Joubert L, Chaix ML et al. Persistence of multidrug-resistant HIV-1 without antiretroviral treatment 2 years after sexual transmission. Antivir Ther 2004; 9: 415-21.
15. Parkin NT, Schapiro JM. Antiretroviral drug resistance in non-subtype B HIV-1, HIV-2 and SIV. Antivir Ther 2004; 9: 3-12.
16. Descamps D, Collin G, Letourneur F et al. Susceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents: in vitro phenotypic and genotypic analyses. J Virol 1997; 71: 8893-8.
17. Descamps D, Apetrei C, Collin G et al. Naturally occurring decreased susceptibility of HIV-1 subtype G to protease inhibitors. AIDS 1998; 12: 1109-11.
18. Weinstock HS, Zaidi I, Heneine W et al. The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. J Infect Dis 2004; 189: 2174-80.
19. Yerly S, von Wyl V, Ledergerber B et al. Swiss HIV Cohort Study. Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey. AIDS 2007; 21: 2223-9.
20. Ghosn J, Pellegrin I, Goujard C et al. French PRIMO Cohort Study Group (ANRS CO 06). HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time. AIDS 2006; 20: 159-70.
21. Chaix ML, Desquilbet L, Descamps D et al. Response to HAART in French patients with resistant HIV-1 treated at primary infection: ANRS Resistance Network. Antivir Ther 2007; 12: 1305-10.
22. Wensing AM, van de Vijver DA, Angarano G el al. SPREAD Programme. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis 2005; 192: 958-66.
23. The SPREAD programme. Transmission of drug-resistant HIV-1 in Europe remains limited to single classes. AIDS 2008; 22: 625-35.
24. NORM. NORM-VET-rapport 2006. www.vetinst.no/nor/Om-Veterinaerinstituttet/ Avdelinger/Avdelingfor-helseovervaaking/Zoonosesenteret/Norm-Vet/ Norm-Norm-Vet-rapporten (25.9. 2008).